Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $5.2 million.
- Rhythm Pharmaceuticals' Gains from Investment Securities rose 67731.28% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 97592.77%. This contributed to the annual value of $6.6 million for FY2024, which is 92.15% up from last year.
- Rhythm Pharmaceuticals' Gains from Investment Securities amounted to $5.2 million in Q3 2025, which was up 67731.28% from -$5.4 million recorded in Q2 2025.
- Rhythm Pharmaceuticals' 5-year Gains from Investment Securities high stood at $27.9 million for Q4 2024, and its period low was -$5.4 million during Q2 2025.
- Moreover, its 5-year median value for Gains from Investment Securities was $1500.0 (2022), whereas its average is $1.7 million.
- Data for Rhythm Pharmaceuticals' Gains from Investment Securities shows a peak YoY increase of 69745000.0% (in 2024) and a maximum YoY decrease of 130707.07% (in 2024) over the last 5 years.
- Over the past 5 years, Rhythm Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then tumbled by 100.08% to -$1000.0 in 2022, then skyrocketed by 500.0% to $4000.0 in 2023, then skyrocketed by 697450.0% to $27.9 million in 2024, then tumbled by 81.21% to $5.2 million in 2025.
- Its last three reported values are $5.2 million in Q3 2025, -$5.4 million for Q2 2025, and -$102000.0 during Q1 2025.